Big Pharma

About 350 million people suffer from rare diseases, most of which are genetic. But the individual disorders affect relatively few people, so there’s little commercial incentive to bring these treatments to market.

Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices have not delivered on those savings.

The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drug-makers are fighting the negotiations with lawsuits.

Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development nor their therapeutic value, research shows.

Pasco County has one of the highest drug overdose death rates in the state. Officials want to fund projects focused on prevention, treatment and recovery.

Drugmakers long ceased to be the only villain of the insulin price scandal. While Lilly is cutting the list price” and others may follow, will other "parties" (i.e. pharmacy benefit managers) cause this price to increase before it hits the pharmacy counter?

The billionaire entrepreneur, Dallas Mavericks owner and "Shark Tank" star is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.

Perspective: Amid skyrocketing drug prices, it’s understandable that patients desperately need help affording medicine, especially when their health is on the line. But these programs create a mirage that perpetuates our health care system’s reckless spending.